Volasertib preclinical activity in high-risk hepatoblastoma.
PLK1
cell cycle
hepatoblastoma
liver
volasertib
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
05 Nov 2019
05 Nov 2019
Historique:
received:
16
04
2019
accepted:
12
08
2019
entrez:
20
11
2019
pubmed:
20
11
2019
medline:
20
11
2019
Statut:
epublish
Résumé
Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. In a chemical screen, we identified volasertib as an agent with
Identifiants
pubmed: 31741706
doi: 10.18632/oncotarget.27237
pii: 27237
pmc: PMC6849653
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6403-6417Informations de copyright
Copyright: Kats et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors have no conflicts of interest with respect to the drugs used in this study.
Références
Oncoimmunology. 2013 Jan 1;2(1):e22620
pubmed: 23482411
Transl Oncol. 2015 Jun;8(3):185-95
pubmed: 26055176
Cancer Sci. 2015 Nov;106(11):1590-5
pubmed: 26471242
Hepatology. 2016 Oct;64(4):1121-35
pubmed: 27115099
Acta Pharmacol Sin. 2012 Jun;33(6):852-8
pubmed: 22669119
Biochim Biophys Acta. 2013 Jan;1835(1):11-27
pubmed: 23006513
Nat Rev Cancer. 2006 Oct;6(10):789-802
pubmed: 16990856
Sci Rep. 2016 Dec 02;6:38347
pubmed: 27910913
World J Transplant. 2014 Dec 24;4(4):294-8
pubmed: 25540737
Oncol Rep. 2019 Jan;41(1):143-153
pubmed: 30320362
Cancer Cell. 2008 Dec 9;14(6):471-84
pubmed: 19061838
Hum Pathol. 2009 Oct;40(10):1512-5
pubmed: 19751877
Mol Cancer Ther. 2009 Nov;8(11):3024-35
pubmed: 19887553
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Br J Cancer. 2014 May 13;110(10):2434-40
pubmed: 24755882
Anticancer Res. 2016 Nov;36(11):5577-5592
pubmed: 27793881
Onco Targets Ther. 2015 Jul 17;8:1761-71
pubmed: 26229484
Invest New Drugs. 2015 Jun;33(3):611-20
pubmed: 25794535
J Clin Oncol. 2012 Apr 1;30(10):1042-9
pubmed: 22370326
J Pediatr Surg. 2001 May;36(5):755-9
pubmed: 11329582
Oncogene. 2004 Aug 5;23(35):5901-11
pubmed: 15221005
Pediatr Hematol Oncol. 2015 Feb;32(1):18-25
pubmed: 24852330
Nat Rev Mol Cell Biol. 2014 Jul;15(7):433-52
pubmed: 24954208
Oncotarget. 2018 Apr 27;9(32):22665-22679
pubmed: 29854306
Am J Cancer Res. 2016 Nov 01;6(11):2476-2488
pubmed: 27904765
Oncotarget. 2017 Jul 26;8(45):78452-78465
pubmed: 29108241
J Pharmacol Exp Ther. 2015 Mar;352(3):579-89
pubmed: 25576074
Cancer Lett. 2019 Mar 31;445:24-33
pubmed: 30611741
Leukemia. 2015 Jan;29(1):11-9
pubmed: 25027517
Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1725-30
pubmed: 19181852
Molecules. 2015 Apr 08;20(4):6113-27
pubmed: 25856061
J Clin Oncol. 2007 Oct 10;25(29):4622-7
pubmed: 17925558
Eur J Cancer. 2012 Dec;48(18):3456-64
pubmed: 22835780
Mol Cancer Ther. 2016 Jul;15(7):1427-35
pubmed: 27330107
Oncotarget. 2018 Jan 8;9(12):10497-10509
pubmed: 29535822
Pediatr Blood Cancer. 2012 Nov;59(5):776-9
pubmed: 22692949
Ann Oncol. 2001 Nov;12(11):1631-41
pubmed: 11822765
J Cell Sci. 1994 Jun;107 ( Pt 6):1509-17
pubmed: 7962193
J Pediatr Hematol Oncol. 2011 Aug;33(6):e226-30
pubmed: 21792028
Clin Cancer Res. 2009 May 1;15(9):3094-102
pubmed: 19383823
Hepatology. 2017 Jan;65(1):104-121
pubmed: 27775819
Hepatology. 2018 Jul;68(1):89-102
pubmed: 29152775
Br J Cancer. 2003 Nov 17;89(10):1849-54
pubmed: 14612891
Biomark Res. 2018 Oct 30;6:31
pubmed: 30450210
Oncotarget. 2015 Apr 20;6(11):8736-49
pubmed: 25826089
Mol Oncol. 2015 Jan;9(1):140-54
pubmed: 25169932
Biochim Biophys Acta. 2010 Dec;1806(2):240-50
pubmed: 20600630